BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

717 related articles for article (PubMed ID: 29463117)

  • 1. Micro-Dystrophin Gene Therapy Goes Systemic in Duchenne Muscular Dystrophy Patients.
    Duan D
    Hum Gene Ther; 2018 Jul; 29(7):733-736. PubMed ID: 29463117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy.
    Duan D
    Mol Ther; 2018 Oct; 26(10):2337-2356. PubMed ID: 30093306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspective on Adeno-Associated Virus Capsid Modification for Duchenne Muscular Dystrophy Gene Therapy.
    Nance ME; Duan D
    Hum Gene Ther; 2015 Dec; 26(12):786-800. PubMed ID: 26414293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression.
    Wang Z; Kuhr CS; Allen JM; Blankinship M; Gregorevic P; Chamberlain JS; Tapscott SJ; Storb R
    Mol Ther; 2007 Jun; 15(6):1160-6. PubMed ID: 17426713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy.
    Zhang Y; Yue Y; Li L; Hakim CH; Zhang K; Thomas GD; Duan D
    Hum Mol Genet; 2013 Sep; 22(18):3720-9. PubMed ID: 23681067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safe and bodywide muscle transduction in young adult Duchenne muscular dystrophy dogs with adeno-associated virus.
    Yue Y; Pan X; Hakim CH; Kodippili K; Zhang K; Shin JH; Yang HT; McDonald T; Duan D
    Hum Mol Genet; 2015 Oct; 24(20):5880-90. PubMed ID: 26264580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress toward Gene Therapy for Duchenne Muscular Dystrophy.
    Chamberlain JR; Chamberlain JS
    Mol Ther; 2017 May; 25(5):1125-1131. PubMed ID: 28416280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy.
    Le Guiner C; Servais L; Montus M; Larcher T; Fraysse B; Moullec S; Allais M; François V; Dutilleul M; Malerba A; Koo T; Thibaut JL; Matot B; Devaux M; Le Duff J; Deschamps JY; Barthelemy I; Blot S; Testault I; Wahbi K; Ederhy S; Martin S; Veron P; Georger C; Athanasopoulos T; Masurier C; Mingozzi F; Carlier P; Gjata B; Hogrel JY; Adjali O; Mavilio F; Voit T; Moullier P; Dickson G
    Nat Commun; 2017 Jul; 8():16105. PubMed ID: 28742067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy.
    Rodino-Klapac LR; Janssen PM; Montgomery CL; Coley BD; Chicoine LG; Clark KR; Mendell JR
    J Transl Med; 2007 Sep; 5():45. PubMed ID: 17892583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models.
    Song Y; Morales L; Malik AS; Mead AF; Greer CD; Mitchell MA; Petrov MT; Su LT; Choi ME; Rosenblum ST; Lu X; VanBelzen DJ; Krishnankutty RK; Balzer FJ; Loro E; French R; Propert KJ; Zhou S; Kozyak BW; Nghiem PP; Khurana TS; Kornegay JN; Stedman HH
    Nat Med; 2019 Oct; 25(10):1505-1511. PubMed ID: 31591596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Gene therapy for muscular dystrophy].
    Takeda S
    No To Hattatsu; 2004 Mar; 36(2):117-23. PubMed ID: 15031985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual AAV Gene Therapy for Duchenne Muscular Dystrophy with a 7-kb Mini-Dystrophin Gene in the Canine Model.
    Kodippili K; Hakim CH; Pan X; Yang HT; Yue Y; Zhang Y; Shin JH; Yang NN; Duan D
    Hum Gene Ther; 2018 Mar; 29(3):299-311. PubMed ID: 28793798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy.
    Pickar-Oliver A; Gough V; Bohning JD; Liu S; Robinson-Hamm JN; Daniels H; Majoros WH; Devlin G; Asokan A; Gersbach CA
    Mol Ther; 2021 Nov; 29(11):3243-3257. PubMed ID: 34509668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adeno-Associated Virus (AAV) Mediated Dystrophin Gene Transfer Studies and Exon Skipping Strategies for Duchenne Muscular Dystrophy (DMD).
    Kawecka K; Theodoulides M; Hasoglu Y; Jarmin S; Kymalainen H; Le-Heron A; Popplewell L; Malerba A; Dickson G; Athanasopoulos T
    Curr Gene Ther; 2015; 15(4):395-415. PubMed ID: 26159373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical development on the frontier: gene therapy for duchenne muscular dystrophy.
    Asher DR; Thapa K; Dharia SD; Khan N; Potter RA; Rodino-Klapac LR; Mendell JR
    Expert Opin Biol Ther; 2020 Mar; 20(3):263-274. PubMed ID: 32031420
    [No Abstract]   [Full Text] [Related]  

  • 16. Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for duchenne muscular dystrophy.
    Ahmad A; Brinson M; Hodges BL; Chamberlain JS; Amalfitano A
    Hum Mol Genet; 2000 Oct; 9(17):2507-15. PubMed ID: 11030755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivery of AAV2/9-microdystrophin genes incorporating helix 1 of the coiled-coil motif in the C-terminal domain of dystrophin improves muscle pathology and restores the level of α1-syntrophin and α-dystrobrevin in skeletal muscles of mdx mice.
    Koo T; Malerba A; Athanasopoulos T; Trollet C; Boldrin L; Ferry A; Popplewell L; Foster H; Foster K; Dickson G
    Hum Gene Ther; 2011 Nov; 22(11):1379-88. PubMed ID: 21453126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Micro-dystrophin and follistatin co-delivery restores muscle function in aged DMD model.
    Rodino-Klapac LR; Janssen PM; Shontz KM; Canan B; Montgomery CL; Griffin D; Heller K; Schmelzer L; Handy C; Clark KR; Sahenk Z; Mendell JR; Kaspar BK
    Hum Mol Genet; 2013 Dec; 22(24):4929-37. PubMed ID: 23863459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene Therapy for Duchenne Muscular Dystrophy.
    Elangkovan N; Dickson G
    J Neuromuscul Dis; 2021; 8(s2):S303-S316. PubMed ID: 34511510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced CRISPR-Cas9 correction of Duchenne muscular dystrophy in mice by a self-complementary AAV delivery system.
    Zhang Y; Li H; Min YL; Sanchez-Ortiz E; Huang J; Mireault AA; Shelton JM; Kim J; Mammen PPA; Bassel-Duby R; Olson EN
    Sci Adv; 2020 Feb; 6(8):eaay6812. PubMed ID: 32128412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.